Eagle Bay Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Eagle Bay Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-63	Closed	-$7.66K	–	833
2024 Q4	$7.66K	Hold	63	–	–	﹤0.01%	608
2024 Q3	$7.87K	Hold	63	–	–	﹤0.01%	846
2024 Q2	$9.95K	Hold	63	–	–	0.01%	558
2024 Q1	$8.16K	Hold	63	–	–	0.01%	620
2023 Q4	$6.08K	Hold	63	–	–	﹤0.01%	603
2023 Q3	$7.64K	Hold	63	–	–	﹤0.01%	634
2023 Q2	$7.21K	Hold	63	–	–	﹤0.01%	629
2023 Q1	$8.68K	Hold	63	–	–	﹤0.01%	612
2022 Q4	$8.16K	Hold	63	–	–	﹤0.01%	630
2022 Q3	$7K	Hold	63	–	–	﹤0.01%	649
2022 Q2	$4.72K	Buy	+63	New	+$4.63K	﹤0.01%	734
2022 Q1	–	Sell	-63	Closed	-$6K	–	879
2021 Q4	$6K	Hold	63	–	–	﹤0.01%	772
2021 Q3	$6K	Hold	63	–	–	﹤0.01%	811
2021 Q2	$5K	Buy	+63	New	+$4.78K	﹤0.01%	753

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Eagle Bay Advisors's SRPT Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 63 shares — an estimated $7.66K sold.

Eagle Bay Advisors first reported a position in SRPT in Q2 2021 and held it in 14 quarters. The position peaked at $9.95K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Eagle Bay Advisors reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 63 Sarepta Therapeutics shares in Q1 2025, an estimated $7.66K.
Eagle Bay Advisors first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 14 quarters.
Eagle Bay Advisors's Sarepta Therapeutics position peaked at $9.95K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.